Funded in part by Lantmännens Forskningsstiftelse, The NovoNordisk Foundation, Lantmännen Research foundation
Sulforaphane reduces hepatic glucose production and improves glucose control in patients with type 2 diabetes
Axelsson AS, Tubbs E, Mecham B, Chacko S, Nenonen HA, Tang Y, Fahey JW, Derry JMJ, Wollheim CB, Wierup N, Haymond MW, Friend SH, Mulder H, Rosengren AH
Science translational medicine · 245 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Controlled clinical trial (classified by our AI screen)
- Studied in
- People, plus animal or lab work
- Main outcome
- Health markers and function
- Intake measured by
- Not stated
Who paid for it
- Funding
- Industry funded
- Nonprofit
- Ragnar Söderbergs stiftelse
- Company
- Lantmännens Forskningsstiftelse
- Nonprofit
- Knut and Alice Wallenberg’s foundation
- Nonprofit
- Ragnar Söderberg Foundation
- Company
- The NovoNordisk Foundation
- Government
- ALF Region Skåne
- Company
- Lantmännen Research foundation
- Nonprofit
- The Hjelt Foundation
- Nonprofit
- The Swedish Foundation for Strategic Research
- Grants
- Lantmännens Forskningsstiftelse (award303397); Ragnar Söderbergs stiftelse (award303395)
Based on 9 listed funder(s).
Publication
- Published
- 2017-06-14 · Sci Transl Med · vol. 9 · issue 394
- Publisher
- American Association for the Advancement of Science
- Cited
- 327 citations · more than 99% of similar papers · 12.1× the field average
- Impact
- Top 10% most cited in its field
- References
- 69 works
- Access
- Open access (repository copy) · CC-BY
- Research areas
- Genomics, phytochemicals, and oxidative stress · Biochemical Acid Research Studies · Diet, Metabolism, and Disease
- Keywords
- Sulforaphane, Type 2 diabetes, Diabetes mellitus, Medicine, Pharmacology, Repurposing, Internal medicine, Chemistry, Endocrinology, Biochemistry, Biology
- MeSH
- liver, cell line, animals, mice, inbred c57bl, humans, mice, diabetes mellitus, type 2, obesity, isothiocyanates, sulfoxides, glucose, blood glucose, hypoglycemic agents, female, male, nf-e2-related factor 2, glycated hemoglobin
14 authors
From SE, US
- A. AxelssonLund University
- Emily TubbsLund University
- Brig Mecham
- Shaji K. ChackoChildren's Nutrition Research Center at Baylor College of Medicine
- Hannah A. NenonenLund University
- Yunzhao TangLund University
Abstract
A potentially useful approach for drug discovery is to connect gene expression profiles of disease-affected tissues ("disease signatures") to drug signatures, but it remains to be shown whether it can be used to identify clinically relevant treatment options. We analyzed coexpression networks and genetic data to identify a disease signature for type 2 diabetes in liver tissue. By interrogating a library of 3800 drug signatures, we identified sulforaphane as a compound that may reverse the disease signature. Sulforaphane suppressed glucose production from hepatic cells by nuclear translocation of nuclear factor erythroid 2-related factor 2 (NRF2) and decreased expression of key enzymes in gluconeogenesis. Moreover, sulforaphane reversed the disease signature in the livers from diabetic animals and attenuated exaggerated glucose production and glucose intolerance by a magnitude similar to that of metformin. Finally, sulforaphane, provided as concentrated broccoli sprout extract, reduced fasting blood glucose and glycated hemoglobin (HbA1c) in obese patients with dysregulated type 2 diabetes.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.